Australian Clinical Labs Ltd (AU:ACL)
ASX:ACL
Want to see AU:ACL full AI Analyst Report?
ACL Stock Chart & Stats
AU$2.09
AU$0.08(2.29%)
At close: 4:00 PM EST
AU$2.09
AU$0.08(2.29%)
Day’s Range― - ―
52-Week RangeAU$1.83 - AU$2.97
Previous CloseN/A
Volume421.17K
Average Volume (3M)867.30K
Market Cap
AU$380.67M
Enterprise ValueAU$812.15M
Total Cash (Recent Filing)AU$23.14M
Total Debt (Recent Filing)AU$453.61M
Price to Earnings (P/E)14.9
Beta0.96
Next Earnings
Aug 26, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend Yield4.6%
Share Statistics
EPS (TTM)0.15
Shares Outstanding187,522,400
10 Day Avg. Volume799,589
30 Day Avg. Volume867,296
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)3.09
Price to Sales (P/S)0.71
P/FCF Ratio3.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.20Price Target Upside5.26% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.16
Revenue Forecast (FY)AU$736.59M
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistent free cash flow growth and high conversion ratios indicate durable internal funding. Strong OCF/NI and FCF/NI ratios mean the business can support dividends, reinvestment, or deleveraging from operating cash, providing financial flexibility over the next several quarters.
Improved Gross MarginsA material improvement in gross margin signals better cost control or pricing power in core pathology services. Coupled with stabilization in revenue, margin recovery is a durable driver of operating leverage and improved earnings capacity if volumes remain steady.
High Return On EquityROE near 19% reflects effective use of shareholder capital and operational efficiency. This level of return supports sustainable shareholder value creation if management maintains margins and cash generation, even as the company balances growth and capital allocation.
Bears Say
High LeverageSignificant leverage increases financial risk and reduces strategic flexibility. Elevated debt levels make the company more sensitive to interest costs and refinancing cycles, constraining capital expenditure, acquisitions or buffer for reimbursement pressure over a multi-quarter horizon.
Low Net ProfitabilityA low net margin limits the company’s ability to absorb adverse reimbursement changes, higher input costs, or invest for growth from operating profit. Even with improved gross margins, limited bottom-line conversion weakens long-term resilience and reinvestment capacity.
Slow Revenue GrowthVery low top-line growth and prior declines suggest limited demand expansion or pricing headwinds in core markets. Structural stagnation in volumes or mix could pressure margins and returns unless the company diversifies services, wins contracts, or increases higher-value testing.
Australian Clinical Labs Ltd News
ACL FAQ
What was Australian Clinical Labs Ltd’s price range in the past 12 months?
Australian Clinical Labs Ltd lowest share price was AU$1.83 and its highest was AU$2.97 in the past 12 months.
What is Australian Clinical Labs Ltd’s market cap?
Australian Clinical Labs Ltd’s market cap is AU$380.67M.
When is Australian Clinical Labs Ltd’s upcoming earnings report date?
Australian Clinical Labs Ltd’s upcoming earnings report date is Aug 26, 2026 which is in 87 days.
How were Australian Clinical Labs Ltd’s earnings last quarter?
Australian Clinical Labs Ltd released its earnings results on Feb 15, 2026. The company reported AU$0.067 earnings per share for the quarter, missing the consensus estimate of AU$0.073 by -AU$0.006.
Is Australian Clinical Labs Ltd overvalued?
According to Wall Street analysts Australian Clinical Labs Ltd’s price is currently Undervalued.
Does Australian Clinical Labs Ltd pay dividends?
Australian Clinical Labs Ltd pays a Semiannually dividend of AU$0.09 which represents an annual dividend yield of 4.6%. See more information on Australian Clinical Labs Ltd dividends here
What is Australian Clinical Labs Ltd’s EPS estimate?
Australian Clinical Labs Ltd’s EPS estimate is 0.1.
How many shares outstanding does Australian Clinical Labs Ltd have?
Australian Clinical Labs Ltd has 187,522,400 shares outstanding.
What happened to Australian Clinical Labs Ltd’s price movement after its last earnings report?
Australian Clinical Labs Ltd reported an EPS of AU$0.067 in its last earnings report, missing expectations of AU$0.073. Following the earnings report the stock price went up 6.768%.
Which hedge fund is a major shareholder of Australian Clinical Labs Ltd?
Currently, no hedge funds are holding shares in AU:ACL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Australian Clinical Labs Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$2.20 (5.26% Upside)
AU$2.20 (5.26% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.73%
12-Months-Change
Fundamentals
Return on Equity
16.35%
Trailing 12-Months
Asset Growth
-3.86%
Trailing 12-Months
Company Description
Australian Clinical Labs Ltd
Australian Clinical Labs Limited provides pathology services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offers its service to private and public hospitals. The company was incorporated in 2020 and is headquartered in Clayton, Australia.
ACL Stock 12 Month Forecast
Average Price Target
AU$2.20
▲(5.26% Upside)
Technical Analysis
Options Prices
Currently, No data available
---